GT Biopharma, Inc. Uncategorized Contracts & Agreements
18 Contracts & Agreements
- Description of the Registrants Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended (Filed With SEC on March 30, 2023)
- Research Agreement with Regents of the University of Minnesota, dated June 16, 2021 (Filed With SEC on March 28, 2022)
- SETTLEMENTAGREEMENT (Filed With SEC on December 28, 2020)
- Consultant Agreement with Michael Handelman, dated November 13, 2020 (Filed With SEC on November 13, 2020)
- Steve Weldon Letter of Resignation, dated November 11, 2020 (Filed With SEC on November 13, 2020)
- Clinical Trial Agreement with University of Minnesota (Filed With SEC on May 15, 2020)
- Consultant Agreement, dated as of February 14, 2018, between the Company and Mr. Cataldo (Filed With SEC on February 21, 2018)
- Amended Preferred Conversion Agreement (Filed With SEC on November 14, 2017)
- Preferred Conversion Agreement (Filed With SEC on November 14, 2017)
- EMPLOYMENTAGREEMENT (Filed With SEC on November 14, 2017)
- RESEARCH AGREEMENT (Filed With SEC on March 13, 2015)
- [OXIS LETTERHEAD] (Filed With SEC on October 9, 2009)
- SECURED PROMISSORYNOTE (Filed With SEC on December 18, 2008)
- ASSETPURCHASE AGREEMENT (Filed With SEC on December 18, 2008)
- AGREEMENT (Filed With SEC on December 10, 2008)
- BRISTOL CAPITAL ADVISORS, LLC (Filed With SEC on June 24, 2008)
- BRISTOLCAPITAL ADVISORS, LLC (Filed With SEC on June 13, 2008)
- Exhibit 10.1 (Filed With SEC on March 4, 2005)